Abstract
Malignant phyllodes tumor is a rare breast tumor, with distant metastases and heterologous differentiation in a few cases. We report a case of malignant phyllodes tumor with liposarcomatous differentiation in the primary tumor and osteosarcomatous differentiation in the lung metastatic tumor. A middle-aged female presented with a well-defined mass in the upper lobe of the right lung measuring 5.0 × 5.0 × 3.0 cm. The patient had a history of malignant phyllodes tumor in the breast. The patient underwent a right superior lobectomy. Histologically, the primary tumor was a typical malignant phyllodes tumor with pleomorphic liposarcomatous differentiation, while the lung metastasis showed osteosarcomatous differentiation without original biphasic features. The phyllodes tumor and heterologous components showed CD10 and p53 expression, and were negative for ER, PR, and CD34. Exome sequencing revealed TP53, TERT, EGFR, RARA, RB1, and GNAS mutations in all three components. Although the lung metastasis were morphologically different from the primary breast tumor, their common origin was demonstrated through immunohistochemical and molecular characterization. Cancer stem cells give rise to tumor heterogeneous cells, and heterologous components in malignant phyllodes tumors may indicate unfavorable prognosis and a greater risk of early recurrence and metastasis.
Introduction
Phyllodes tumor is an uncommon, fibroepithelial neoplasm with leaf-like stromal fronds that can be classified as benign, borderline, or malignant based on the histological characteristics. Malignant phyllodes tumors (MPTs) commonly occur between the ages of 45 and 49 years (1). Marked stromal nuclear pleomorphism and stromal overgrowth, increased mitoses, and infiltrative borders can usually be seen. Some tumors may show heterologous differentiation, including liposarcomatous, fibrosarcomatous, osteosarcomatous, chondrosarcomatous, and rhabdomyosarcomatous structures, indicating a poorer prognosis (2–4). Distant metastases occur in 23% of MPTs and show histological features similar to the primary tumor (5). We report a case of pleomorphic liposarcomatous primary MPT with osteosarcomatous lung metastasis.
Case presentation
A 57-year-old female was admitted with a right lung mass detected on physical examination 3 days previously. Chest computed tomography revealed a soft-tissue density mass in the upper lobe of the right lung near the hilum, with bronchial obstruction in the anterior segment of the upper lobe and a patchy fuzzy shadow distally (Figure 1). Laboratory findings, including tumor markers, were within the normal ranges. The patient had a history of MPT of the breast with liposarcomatous differentiation removed 1.5 years previously. Then, a right superior lobectomy was performed. No adjuvant treatments were administered after lung resection, and the patient underwent an uneventful recovery without tumor recurrence during 1 year of follow-up. This study was approved by the 960th Hospital’s institutional ethical committee, and performed in accordance with the principles embodied in the Declaration of Helsinki.
Figure 1
Chest computed tomography showing a soft-tissue density mass in the upper lobe of the right lung. (A) lung window; (B) mediastinal window.
Macroscopic examination showed a multinodular, solid, grey-white, medium-textured mass measuring 5.0 × 5.0 × 3.0 cm. Histopathologically, the tumor was composed of spindle, ovoid, and osteoclast-like giant cells with focal osteoid formation. Atypical elongated cells had considerable morphological diversity with enlarged, hyperchromatic, and lobulated nuclei. The tumor cells were arranged in sheets or intertwined fascicles. There was multifocal abundance of osteoclast-like multi-nucleated giant cells. Some portions of the mesenchyme contained areas of osteoid formation (Figures 2A,B). Local necrosis and cystic changes were also noted. The mitotic index was 12 mitoses per 10 high-power fields (HPF). Irregular tumor nodules bulged into the surrounding lung tissue. Hilar nodes were free of tumor cells. The immunohistochemistry analysis is shown in Table 1 and Figures 2C,D. The lung tumor was pathologically diagnosed as metastatic breast MPT with osteosarcomatous differentiation. The lung tumor was histologically different from the original breast tumor, with significant cell density and atypia.
Figure 2
Histopathological and immunohistochemical characteristics of the MPTs. (A) Atypical elongated cells had considerable diversity in the lung metastatic tumors (haematoxylin and eosin staining, 100×). (B) Abundant osteoclasts and osteoid formation were observed (haematoxylin and eosin staining, 100×). Tumor cells were positive for CD10 (C) and SATB-2 (D; immunohistochemical staining, 200×). (E) The MPT (left) and pleomorphic liposarcomatous differentiation (right) were mixed without clear boundaries in the primary breast MPT (haematoxylin and eosin staining, 40×). (F) Tumor cells with pleomorphic liposarcomatous differentiation were positive for S-100 (right; immunohistochemical staining, 40×).
Table 1
| Antibody | Malignant phyllodes tumor | Liposarcomatous differentiation | Osteosarcomatous differentiation |
|---|---|---|---|
| CD10 | + | + | + |
| P53 | + | + | + |
| ER | − | − | − |
| PR | − | − | − |
| CD34 | − | − | − |
| CD117 | local + | − | − |
| SMA | local + | − | local + |
| Actin | local + | − | local + |
| S-100 | − | + | − |
| SATB-2 | − | − | + |
| Ki-67 | 25% | 35% | 30% |
Immunohistochemical characteristics of different components of the malignant phyllodes tumor.
The pathological features of the primary breast tumor represented a mixture of phyllodes tumor and liposarcoma (Figures 2E,F). Mesenchymal lesions had caused marked narrowing of the tubular epithelial structures. There was some mesenchymal cell atypia with large, irregular, hyperchromatic nuclei. Pleomorphic liposarcomatous components were observed. Eight mitoses per 10 HPF and 2 per 10 HPF were observed in areas of phyllodes tumor and liposarcomatous differentiation, respectively. The tumor had poorly defined borders but there was no obvious axillary lymph node enlargement.
Three different morphological components of MPT and normal breast tissue were detected using GENESEEQ PRIME™ high-throughput DNA sequencing (Geneseeq Technology Inc., Nanjing, China), which targets the coding regions of 425 cancer-related genes. All three components showed TP53, TERT, EGFR, RARA, RB1, and GNAS gene mutations with similar frequencies (Table 2). MET and PREX2 missense mutations were detected only in the liposarcomatous component and lung metastasis, respectively, with low mutation frequency.
Table 2
| Gene | Alteration | ExonicFunc | Malignant phyllodes tumor | Liposarcomatous differentiation | Osteosarcomatous differentiation |
|---|---|---|---|---|---|
| TERT | c.-124C > T | upstream_gene_variant | 34.97% | 36.36% | 40.71% |
| EGFR | c.3114 + 1G > T | splice_donor_variant | 35.71% | 32.35% | 33.55% |
| TP53 | c.832C > A | missense_variant | 67.44% | 60.87% | 58.87% |
| RARA | c.701_703delAGT | inframe_deletion | 57.58% | 78.26% | 58.04% |
| RB1 | c.1421G > C | missense_variant | 75.00% | 55.56% | 47.01% |
| GNAS | c.1727C > A | missense_variant | 22.14% | 35.42% | 54.52% |
| MET | c.901A > C | missense_variant | - | 25.00% | - |
| PREX2 | c.2570C > A | missense_variant | - | - | 15.61% |
Mutation frequencies of different components in the malignant phyllodes tumor.
Discussion
Breast MPTs are rare tumors that account for <1% of all breast tumors. Recurrences occur in 23–30% of the cases (6, 7), but few tumors metastasize to other parts of the body, including lungs, bones, ovaries, brain, and pancreas, mainly through the hematogenous route (8–10). Our patient underwent a mastectomy for breast MPT, but the tumor metastasized to the lung 1.5 years after the surgery, indicating the aggressive nature of the MPT. Surgical excision with clear margins without lymphadenectomy remains the cornerstone of treatment for localized MPTs. The use of chemotherapy remains controversial (11). The treatment of metastatic tumors involves chemotherapy using conventional drugs for the sarcomatoid component. The patient chose a conservative treatment strategy, and no adjuvant therapy was performed after pulmonary lobectomy. No tumor recurrence was observed during 1 year follow-up.
Cancer stem cells give rise to tumor heterogeneous cells and form heterogeneous components. Liposarcomatous differentiation is common in heterogeneous MPTs (4). Unlike well-differentiated liposarcomas, pleomorphic liposarcomas increase the metastatic risk of breast phyllodes tumors. In the present case, breast MPT with pleomorphic liposarcomatous differentiation metastasized 1.5 years after mastectomy with negative margins, indicating the influence on the malignant potential. Osteosarcomatous differentiation of MPTs is rare, accounting for 1.3% of breast phyllodes tumors (12). The osteosarcomatous component comprises a variable percentage of MPTs, ranging from 25 to 100%. Osteosarcomatous differentiation in primary or recurrent tumors indicates a poor prognosis. Silver et al. (12) investigated 22 cases of osteosarcomatous MPTs and found that their biological behavior was similar to that of soft tissue osteosarcomas, with distant metastases and tumor-related deaths occurring in 38 and 33% of the patients, respectively. Osteosarcomatous differentiation only in the metastatic tumors is rare in breast MPTs. The definitive diagnosis was based on the histopathology, immunochemistry, and the molecular characteristics. Tsubochi et al. (13) reported a similar case with osteosarcomatous component detected only in the lung metastasis; the patient remained disease-free 2 years after pulmonary lobectomy. Despite liposarcomatous differentiation of the primary breast tumor in this patient, there was no tumor recurrence during the 1-year follow-up after lung tumor resection. Osteosarcomatous breast MPTs have been reported to be biologically aggressive tumors characterized by early recurrence and hematogenous metastasis, frequently to the lungs (14). However, the prognostic value of osteosarcomatoid differentiation in MPT metastases needs to be confirmed in further studies.
In this case, only osteosarcomatoid component was found in the metastatic lung tumor; no MPT or lipomarcomatoid components were observed. It is important to distinguish these tumors from other neoplasms that may contain osseous structures, such as primary extraosseous osteosarcomas, carcinosarcomas, and ossifying stromal tumors. Immunohistochemical and molecular genetic analyses may be used for differential diagnosis. In the present case, the three components were positive for CD10 and p53 on immunohistochemical staining and had similar molecular mutation characteristics. To the best of our knowledge, the genetic characteristics of different heterologous components of MPTs have not been previously compared used high-throughput sequencing.
In conclusion, breast MPTs may develop heterologous differentiation in the primary or metastatic tumors, which indicates an unfavorable prognosis. This was a unique case with pleomorphic liposarcomatous differentiation in the primary tumor and osteosarcomatous differentiation in the lung metastatic tumor. The heterologous components showed immunohistochemical and molecular characteristics similar to MPTs. Careful follow-up is essential in MPT patients with heterologous differentiation.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Ethics statement
The studies involving human participants were reviewed and approved by the 960th Hospital’s institutional ethical committee. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.
Author contributions
RL: conceptualization, data curation, and writing – original draft. JX, WL, BJ, FS, and ZW: data curation and investigation. PL: conceptualization, project administration, and writing – review and editing. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- MPTs
malignant phyllodes tumors
- HPF
high power fields
Abbreviations
References
1.
Lissidini G Mule A Santoro A Papa G Nicosia L Cassano E et al . Malignant phyllodes tumor of the breast: a systematic review. Pathologica. (2022) 114:111–20. doi: 10.32074/1591-951X-754
2.
Yom CK . Malignant phyllodes of breast. Adv Exp Med Biol. (2021) 1187:601–12. doi: 10.1007/978-981-32-9620-6_32
3.
Zhou P Zhang Q Zhu J Li P . Molecular characterization of pleomorphic liposarcomatous differentiation in malignant phyllodes tumor of the breast: a case report. Pathol Res Pract. (2021) 224:153489. doi: 10.1016/j.prp.2021.153489
4.
Koh VCY Thike AA Nasir NDM Yip GWC Bay BH Tan PH . Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast. Virchows Arch. (2018) 472:615–21. doi: 10.1007/s00428-017-2257-1
5.
Altiok M Kurt F . Factors effective on recurrence and metastasis in phyllodes tumors. Niger J Clin Pract. (2022) 25:425–31. doi: 10.4103/njcp.njcp_1374_21
6.
Kim S Kim JY Kim DH Jung WH Koo JS . Analysis of phyllodes tumor recurrence according to the histologic grade. Breast Cancer Res Treat. (2013) 141:353–63. doi: 10.1007/s10549-013-2684-x
7.
Lim RS Cordeiro E Lau J Lim A Roberts A Seely J . Phyllodes tumors-the predictors and detection of recurrence. Can Assoc Radiol J. (2021) 72:251–7. doi: 10.1177/0846537119899553
8.
Wada A Hayashi N Endo F Tsunoda H Yoshida A Suzuki K et al . Repeat recurrence and malignant transition of phyllodes tumors of the breast. Breast Cancer. (2018) 25:736–41. doi: 10.1007/s12282-018-0882-4
9.
Lee SE Bae YK Choi JH . Pancreatic metastasis from malignant phyllodes tumor of the breast. Yeungnam Univ J Med. (2021) 38:78–82. doi: 10.12701/yujm.2020.00759
10.
Tada Y Yasunaga M Tomonobe H Yamada Y Hori E Okugawa K et al . A case of malignant phyllodes tumor of the breast metastasizing to the ovary. Int J Surg Pathol. (2022) 30:427–31. doi: 10.1177/10668969211056912
11.
Rayzah M . Phyllodes tumors of the breast: a literature review. Cureus. (2020) 12:e10288. doi: 10.7759/cureus.10288
12.
Silver SA Tavassoli FA . Osteosarcomatous differentiation in phyllodes tumors. Am J Surg Pathol. (1999) 23:815–21. doi: 10.1097/00000478-199907000-00010
13.
Tsubochi H Sato N Kaimori M Imai T . Osteosarcomatous differentiation in lung metastases from a malignant phyllodes tumour of the breast. J Clin Pathol. (2004) 57:432–4. doi: 10.1136/jcp.2003.012336
14.
Singhal V Chintamani CJM . Osteogenic sarcoma of the breast arising in a cystosarcoma phyllodes: a case report and review of the literature. J Med Case Rep. (2011) 5:293. doi: 10.1186/1752-1947-5-293
Summary
Keywords
malignant phyllodes tumor, osteosarcomatous differentiation, liposarcomatous differentiation, tumor metastasis, cancer stem cells, case report
Citation
Liu R, Xue J, Liu W, Jiang B, Shi F, Wang Z and Li P (2023) Case report: Osteosarcomatous differentiation in the lung metastasis of a malignant phyllodes tumor. Front. Med. 10:1141353. doi: 10.3389/fmed.2023.1141353
Received
10 January 2023
Accepted
06 March 2023
Published
21 March 2023
Volume
10 - 2023
Edited by
Piergiuseppe Colombo, Humanitas University, Italy
Reviewed by
Luigi M. Terracciano, University of Basel, Switzerland; Mingyang Li, Air Force Medical University, China
Updates
Copyright
© 2023 Liu, Xue, Liu, Jiang, Shi, Wang and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhenzheng Wang, pla456wzz@163.comPeifeng Li, lipeifeng00@hotmail.com
†These authors have contributed equally to this work and share co-first authorship
This article was submitted to Pathology, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.